CHYIFENG JAN

CHYIFENG JAN


Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2006 in Epidemiologic Reviews
Verified
Journal Article
Open access
PDF file
YCYin-Chu Chien
Yin-Chu Chien
CJCHYIFENG JAN
CHYIFENG JAN
HKHsu-Sung Kuo
Hsu-Sung Kuo
The national hepatitis B vaccination program in Taiwan is considered one of the most successful and effective public health programs to control chronic hepatitis B infection in the past 20 years. This review illustrates how to implement a successful hepatitis B vaccination program based on Taiwan's experience. Several important controlled randomized clinical trials on hepatitis B immunoglobulin and vaccine in Taiwan demonstrated an 80–90% protective effect among infants of mothers who were positive for either hepatitis B envelope antigen or hepatitis B surface antigen. A series of prevalence surveys on children born before and after the national vaccination program began disclosed a steady decrease in seroprevalence of hepatitis B surface antigen in Taiwan, with 78–87% effectiveness after the national vaccination program was launched. Studies on the secular trend of liver disease risk also documented a 68% decline in mortality from fulminant hepatitis in infants and a 75% decrease in the incidence of hepatocellular carcinoma in children 6–9 years of age after the national vaccination program began. In conclusion, since 1984, the national hepatitis B vaccination program has been successful in preventing acute and chronic liver diseases in Taiwan.

10 January 2006 in International Journal of Obesity
Verified
Journal Article
Closed access
CJCHYIFENG JAN
CHYIFENG JAN
CCC-J Chen
C-J Chen
YCY-H Chiu
Y-H Chiu
LCL-S Chen
L-S Chen
HWH-M Wu
H-M Wu
TCTony Hsiu-Hsi Chen
Tony Hsiu-Hsi Chen

22 April 2010 in Hepatology
Verified
Journal Article
Open access
PDF file
CJCHYIFENG JAN
CHYIFENG JAN
Kuo-Chin HuangKuo-Chin Huang
Kuo-Chin Huang
YCYin-Chu Chien
Yin-Chu Chien
DGDonald E. Greydanus
Donald E. Greydanus
DDDele H. Davies
Dele H. Davies
DCDing-Shinn Chen
Ding-Shinn Chen
The long-term protection of hepatitis B (HB) vaccination has been debated for years. The purpose here was to evaluate the kinetic changes of antibody to HB surface antigen (anti-HBs) and define immune memory of the HB vaccine among college students who had previously received full neonatal immunization against HB. In all, 127 college students aged 18-23 years born after July 1984 who had completed HB vaccination and were seronegative for all three HB viral markers, including HB surface antigen (HBsAg), antibody to HB core protein (anti-HBc), and anti-HBs, were recruited. They received three doses of HB vaccine at enrollment, 1 month and 6 months after enrollment. Their anti-HBs titers were assayed at enrollment, 7-10 days, 1 month, 6 months, and 7 months following the first dose of HB vaccine. The anti-HBs seroprotective rates for subjects 7-10 days, 1 month, 6 months, and 7 months postvaccination were 20.5%, 75.6%, 94.5%, and 99.2%, respectively. Those who were seroprotective at 7 to 10 days after one dose of HB vaccine booster developed significantly higher levels of anti-HBs at 1 and 6 months than those not developing seroprotective anti-HBs response at an earlier timepoint. Conclusion: At least one-quarter of HB vaccinees have lost their immune memory to the HB vaccine when entering college. Immune memory to HB vaccine was identified by early seroconversion, which was present in only 20% of vaccinees in the present study. To ensure higher than 90% anti-HBs seroconversion rates, at least 2 doses of HB booster vaccines are recommended for at-risk youths who received complete HB vaccinations in neonatal or infant periods but are seronegative for HBsAg, anti-HBs, and anti-HBc in adolescence. (Hepatology 2010;)

1 September 2016 in Clinical Gastroenterology and Hepatology
Verified
Journal Article
Closed access
YNYen-Hsuan Ni
Yen-Hsuan Ni
MCMei-Hwei Chang
Mei-Hwei Chang
CJCHYIFENG JAN
CHYIFENG JAN
HHHong-Yuan Hsu
Hong-Yuan Hsu
HCHuey-Ling Chen
Huey-Ling Chen
DCDing-Shinn Chen
Ding-Shinn Chen

19 January 2009 in Artificial Organs
Verified
Journal Article
Closed access
PDF file
TKTze‐Wah Kao
Tze‐Wah Kao
MLMei‐Shu Lai
Mei‐Shu Lai
TTTun‐Jun Tsai
Tun‐Jun Tsai
CJCHYIFENG JAN
CHYIFENG JAN
WCWei-Chu Chie
Wei-Chu Chie
WCWan-Yu Chen
Wan-Yu Chen

4 February 2014 in Hepatology
Verified
Journal Article
Open access
PDF file
YCYin-Chu Chien
Yin-Chu Chien
CJCHYIFENG JAN
CHYIFENG JAN
CCChun-Ju Chiang
Chun-Ju Chiang
HKHsu-Sung Kuo
Hsu-Sung Kuo
SYSan-Lin You
San-Lin You
CCChien-Jen Chen
Chien-Jen Chen
Hepatitis B immunization has been documented to prevent fulminant hepatic failure (FHF) and hepatocellular carcinoma (HCC) by historical comparison studies in Taiwan. This study aimed to assess long-term risks and predictors of various liver diseases associated with incomplete immunization in 3.8 million vaccinees. Profiles of the National Hepatitis B Immunization Registry, National Cancer Registry, and National Death Certification Registry were linked to ascertain newly diagnosed cases of HCC and deaths from FHF and chronic liver diseases (CLDs) from infancy to early adulthood of 3,836,988 newborn vaccinees. Cox's proportional hazards models were used to estimate hazard ratios (HRs) for various risk predictors. There were 49 newly developed cases of HCC, 73 deaths from FHF, and 74 deaths from CLDs during the follow-up of 41,854,715 person-years. There were striking differences between unvaccinated and vaccinated newborns after the launch of a national immunization program for HCC incidence (0.293 vs. 0.117 per 100,000 person-years), FHF mortality (0.733 vs. 0.174 per 100,000 person-years), and CLD mortality (2.206 vs. 0.177 per 100,000 person-years). Among vaccinees, incomplete immunization was the most important risk predictor of HCC, FHF, and CLDs, showing an HR (95% confidence interval, P value) of 2.52 (1.25-5.05; P = 0.0094), 4.97 (3.05-8.11; P < 0.0001), and 6.27 (3.62-10.84; P < 0.0001), respectively, after adjustment for maternal hepatitis B serostatus. Conclusion : Hepatitis B immunization can significantly prevent the long-term risk of HCC, FHF, and CLDs from infancy to early adulthood. Incomplete immunization with hepatitis B immunoglobulin or vaccines was the most important risk predictor of the liver disease among vaccinees. (Hepatology 2014;60:125–132)